CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hepatobiliary cancers.
  
  LEARNING OBJECTIVES

  • Consider age, performance status, degree of liver function and other clinical and logistical factors in the selection of first- and later-line therapy for unresectable or metastatic hepatocellular carcinoma (HCC).
  • Appreciate Phase III data leading to the FDA approval of novel first-line treatment strategies for unresectable or metastatic HCC, and discuss their optimal integration into clinical care.
  • Evaluate the rationale for and available and emerging data with the use of anti-PD-1/PD-L1 antibodies in combination with anti-CTLA-4 antibodies for HCC to determine the current and potential role of these novel regimens.
  • Establish an evidence-based approach to the selection and sequencing of available therapeutic options for progressive HCC.
  • Discuss the biologic justification for the evaluation of immune checkpoint inhibitors for advanced biliary tract cancers and review available and emerging data with anti-PD-1/PD-L1 antibody-based treatment approaches.
  • Recognize the molecular heterogeneity of biliary tract cancers, and appreciate the biologic rationale for efforts to exploit documented abnormalities in patients with these diseases.
  • Assess key data sets supporting the FDA approvals of fibroblast growth factor receptor (FGFR) inhibitors for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement, and consider how these agents can be appropriately and safely integrated into clinical management algorithms.
  • Develop an understanding of available clinical trial findings with isocitrate dehydrogenase 1 (IDH1) inhibitors for patients with advanced cholangiocarcinoma and an IDH1 mutation, and identify individuals for whom treatment with this novel strategy is warranted.
  • Develop an understanding of the side effects and toxicities associated with targeted agents and immunotherapeutic approaches used in the management of advanced HCC and other biliary tract cancers, and intervene with early and effective responses to various adverse events.
  • Recall available and emerging data with investigational agents and strategies currently in clinical testing for hepatobiliary cancers, and refer eligible patients for trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Ghassan Abou-Alfa, MD, MBA
  Attending
  Memorial Sloan Kettering Cancer Center
  Professor
  Weill Cornell College at Cornell University
  New York, New York
  
  Consulting Agreements: Adicet Bio, Alnylam Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Autem Medical, BeiGene Ltd, Berry Genomics, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Cend Therapeutics, CytomX Therapeutics, Eisai Inc, Exelixis Inc, Flatiron Health, Genentech, a member of the Roche Group, Genoscience Pharma, Helio Health, Helsinn Healthcare SA, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Nerviano Medical Sciences, NewBridge Pharmaceuticals, Novartis, QED Therapeutics, Rafael Pharmaceuticals Inc, RedHill Biopharma Ltd, Servier Pharmaceuticals LLC, Silenseed Ltd, Sobi, Vector Pharma, Yiviva; Contracted Research: Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BioNTech, Bristol-Myers Squibb Company, Celgene Corporation, Flatiron Health, Genentech, a member of the Roche Group, Genoscience Pharma, Incyte Corporation, Polaris Group, Puma Biotechnology Inc, QED Therapeutics, Silenseed Ltd, Yiviva.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, the parent company of GHI, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by an educational grant from AstraZeneca Pharmaceuticals LP.
  
  Release date: July 2022
  Expiration date: July 2023